Adherence to glucagon‐like peptide ‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
Authors' conclusion
Approximately one in five patients discontinued GLP-1RA therapy within the first 12 months and only half were adherent. Overall, lower socioeconomic status and higher comorbidity burden were associated with higher risk of discontinuing GLP-1RA treatment.
Study context
- Population
- First-time users of GLP-1 RA with T2D, aged ≥18 years, 2007 to 2020, Danish registries; mean age 58.6 years, 42.7% female, median T2D duration 6.8 years, median HbA1c 65 mmol/mol
- Participants
- 44,343 first-time users
- Outcome
- Adherence to GLP-1 RA therapy (medication possession ratio >0.80) and discontinuation of GLP-1 RA therapy
- Follow-up
- 6- and 12-month follow-ups
Methodological detailsreal-world data, Danish registries, multivariable cause-specific Cox regression
- Real-world data
- Danish registries
- Multivariable cause-specific Cox regression
Main finding
As reported in the abstract
6 and 12 months
Absolute risk of discontinuation within 6 months
14.2%
95% CI 13.9–14.6
Absolute risk of discontinuation within 12 months
21.2%
95% CI 20.8–21.5
Adherent at 6 months
50.4%
Adherent at 12 months
48.6%
Observational data: associations, not effects.
Further findings
Factors associated with risk of discontinuation (multivariable model)
- Younger (<40 years) and older age (>75 years), higher Charlson Comorbidity Index score, lower household income, high school and longer university degree as educational attainment, and longer diabetes duration associated with higher risk of discontinuation
Original publication
Adherence to glucagon‐like peptide ‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study. Diabetes Obes Metab. Published 31 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →